Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 13 studies | 23% ± 8% | |
T cell | 8 studies | 20% ± 4% | |
natural killer cell | 6 studies | 19% ± 4% | |
CD4-positive, alpha-beta T cell | 6 studies | 22% ± 10% | |
naive B cell | 5 studies | 21% ± 6% | |
dendritic cell | 5 studies | 35% ± 7% | |
macrophage | 5 studies | 26% ± 8% | |
regulatory T cell | 5 studies | 19% ± 3% | |
CD8-positive, alpha-beta T cell | 4 studies | 22% ± 6% | |
epithelial cell | 4 studies | 38% ± 23% | |
pro-B cell | 4 studies | 32% ± 8% | |
erythrocyte | 4 studies | 28% ± 9% | |
T follicular helper cell | 4 studies | 20% ± 3% | |
placental villous trophoblast | 3 studies | 28% ± 12% | |
myeloid cell | 3 studies | 21% ± 3% | |
platelet | 3 studies | 17% ± 1% | |
endothelial cell | 3 studies | 21% ± 4% | |
germinal center B cell | 3 studies | 28% ± 4% | |
glutamatergic neuron | 3 studies | 31% ± 11% | |
gamma-delta T cell | 3 studies | 24% ± 6% | |
hepatocyte | 3 studies | 30% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2681.66 | 1445 / 1445 | 100% | 83.20 | 183 / 183 |
ovary | 100% | 2509.79 | 180 / 180 | 100% | 69.28 | 430 / 430 |
uterus | 100% | 3297.99 | 170 / 170 | 100% | 80.43 | 459 / 459 |
breast | 100% | 1437.43 | 459 / 459 | 100% | 147.53 | 1115 / 1118 |
stomach | 100% | 1521.19 | 359 / 359 | 100% | 43.88 | 285 / 286 |
prostate | 100% | 2276.43 | 245 / 245 | 100% | 50.91 | 500 / 502 |
liver | 100% | 3365.52 | 226 / 226 | 100% | 67.31 | 404 / 406 |
intestine | 100% | 1695.68 | 966 / 966 | 99% | 43.17 | 524 / 527 |
lung | 99% | 1494.71 | 575 / 578 | 99% | 69.39 | 1148 / 1155 |
bladder | 100% | 2634.71 | 21 / 21 | 98% | 49.37 | 496 / 504 |
pancreas | 99% | 1262.33 | 325 / 328 | 98% | 38.24 | 174 / 178 |
kidney | 100% | 1198.34 | 89 / 89 | 96% | 35.36 | 862 / 901 |
skin | 100% | 2781.85 | 1809 / 1809 | 94% | 28.12 | 445 / 472 |
brain | 95% | 1046.74 | 2501 / 2642 | 98% | 27.90 | 691 / 705 |
thymus | 99% | 904.80 | 646 / 653 | 90% | 25.57 | 545 / 605 |
adrenal gland | 100% | 7294.45 | 258 / 258 | 87% | 67.91 | 200 / 230 |
peripheral blood | 100% | 4608.12 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 2667.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 114.43 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 32.53 | 1 / 1 |
blood vessel | 100% | 2276.00 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 1549.89 | 1202 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 81.69 | 28 / 29 |
heart | 95% | 1057.97 | 815 / 861 | 0% | 0 | 0 / 0 |
muscle | 92% | 724.03 | 737 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 49% | 8.49 | 39 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043154 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0042752 | Biological process | regulation of circadian rhythm |
GO_0031396 | Biological process | regulation of protein ubiquitination |
GO_0060070 | Biological process | canonical Wnt signaling pathway |
GO_1990000 | Biological process | amyloid fibril formation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0007264 | Biological process | small GTPase-mediated signal transduction |
GO_2001237 | Biological process | negative regulation of extrinsic apoptotic signaling pathway |
GO_0006915 | Biological process | apoptotic process |
GO_0048511 | Biological process | rhythmic process |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0005769 | Cellular component | early endosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0043025 | Cellular component | neuronal cell body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0031624 | Molecular function | ubiquitin conjugating enzyme binding |
Gene name | SIAH2 |
Protein name | E3 ubiquitin-protein ligase SIAH2 (EC 2.3.2.27) (RING-type E3 ubiquitin transferase SIAH2) (Seven in absentia homolog 2) (Siah-2) (hSiah2) Siah E3 ubiquitin protein ligase 2 |
Synonyms | |
Description | FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins . E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates . Mediates E3 ubiquitin ligase activity either through direct binding to substrates or by functioning as the essential RING domain subunit of larger E3 complexes . Triggers the ubiquitin-mediated degradation of many substrates, including proteins involved in transcription regulation (GPS2, POU2AF1, PML, NCOR1), a cell surface receptor (DCC), an antiapoptotic protein (BAG1), and a protein involved in synaptic vesicle function in neurons (SYP) . Mediates ubiquitination and proteasomal degradation of DYRK2 in response to hypoxia . It is thereby involved in apoptosis, tumor suppression, cell cycle, transcription and signaling processes . Has some overlapping function with SIAH1 . Triggers the ubiquitin-mediated degradation of TRAF2, whereas SIAH1 does not . Promotes monoubiquitination of SNCA . Regulates cellular clock function via ubiquitination of the circadian transcriptional repressors NR1D1 and NR1D2 leading to their proteasomal degradation . Plays an important role in mediating the rhythmic degradation/clearance of NR1D1 and NR1D2 contributing to their circadian profile of protein abundance . Mediates ubiquitination and degradation of EGLN2 and EGLN3 in response to the unfolded protein response (UPR), leading to their degradation and subsequent stabilization of ATF4 (By similarity). Also part of the Wnt signaling pathway in which it mediates the Wnt-induced ubiquitin-mediated proteasomal degradation of AXIN1. . |
Accessions | ENST00000482706.1 ENST00000312960.4 O43255 C9J9D7 |